CD44 and cancer: Fourth, although inflammation-associated cancers accumulate activated immune cells with upregulated transferrin receptors and CD44 variants and may take up the Tf-PEG-PEI-nanoparticles, there will be no deletion of CD44 variant because the promoter is not lymphocyte specific.